- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc stock price live, this page displays NASDAQ PHAT stock exchange data. View the PHAT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Phathom Pharmaceuticals Inc real time stock price chart below.
What Is the Phathom Pharmaceuticals Inc Stock Price Today?
The Phathom Pharmaceuticals Inc stock price today is 12.58.
What Is the Stock Symbol for Phathom Pharmaceuticals Inc?
The stock symbol for Phathom Pharmaceuticals Inc is ""PHAT.""
What Stock Exchange Does Phathom Pharmaceuticals Inc Trade On?
Phathom Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Phathom Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Phathom Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHAT quote. (ISIN: US71722W1071)
What Is the Phathom Pharmaceuticals Inc Stock Price Today?
The Phathom Pharmaceuticals Inc stock price today is 12.58.
What Is the Stock Symbol for Phathom Pharmaceuticals Inc?
The stock symbol for Phathom Pharmaceuticals Inc is ""PHAT.""
What Stock Exchange Does Phathom Pharmaceuticals Inc Trade On?
Phathom Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Phathom Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Phathom Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHAT quote. (ISIN: US71722W1071)
NASDAQ
Currency in USD
Fair Value
An estimate of a Phathom Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.42
12.67
52 wk Range
2.21
19.71
PHAT Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
PHAT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Phathom Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.4212.67
52 wk Range
2.2119.71
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHAT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Phathom Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Phathom Pharmaceuticals Inc Company Profile
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- Q2 2025 revenue of $39.5M beat forecast by 8.58%; EPS loss of $0.79 narrower than expected $0.91 loss
- Stock surged 12.21% pre-market; company aims for profitability by 2026, focusing on gastroenterology market
- Full-year 2025 revenue guidance of $165M-$175M surpasses analyst consensus; 196% revenue growth forecast for FY2025
- Cost-cutting measures underway; strong liquidity with current ratio of 3.58; stock slightly undervalued per analysts
- CEO highlights Vaquesna's potential in treating persistent GERD symptoms; company exploring international expansion
Last Updated: 07/08/2025, 15:56
Read Full TranscriptCompare PHAT to Peers and Sector
Metrics to compare | PHAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHATPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −4.0x | −0.5x | |
PEG Ratio | −0.29 | 0.36 | 0.00 | |
Price/Book | −2.2x | 2.7x | 2.6x | |
Price / LTM Sales | 7.7x | 1.8x | 3.3x | |
Upside (Analyst Target) | 72.9% | 66.1% | 38.7% | |
Fair Value Upside | Unlock | 9.8% | 5.0% | Unlock |
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.79 / -0.91
Revenue / Forecast
39.50M / 36.38M
People Also Watch
FAQ
What Stock Exchange Does Phathom Pharma Trade On?
Phathom Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Phathom Pharma?
The stock symbol for Phathom Pharma is "PHAT."
What Is the Phathom Pharma Market Cap?
As of today, Phathom Pharma market cap is 872.00M.
What Is Phathom Pharma's Earnings Per Share (TTM)?
The Phathom Pharma EPS (TTM) is -4.71.
When Is the Next Phathom Pharma Earnings Date?
Phathom Pharma will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is PHAT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Phathom Pharma Stock Split?
Phathom Pharma has split 0 times.
How Many Employees Does Phathom Pharma Have?
Phathom Pharma has 427 employees.
What is the current trading status of Phathom Pharma (PHAT)?
As of 27 Aug 2025, Phathom Pharma (PHAT) is trading at a price of 12.58, with a previous close of 12.58. The stock has fluctuated within a day range of 11.42 to 12.67, while its 52-week range spans from 2.21 to 19.71.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.